Literature DB >> 24326612

An orthotopic bladder cancer model for gene delivery studies.

Laura Kasman1, Christina Voelkel-Johnson.   

Abstract

Bladder cancer is the second most common cancer of the urogenital tract and novel therapeutic approaches that can reduce recurrence and progression are needed. The tumor microenvironment can significantly influence tumor development and therapy response. It is therefore often desirable to grow tumor cells in the organ from which they originated. This protocol describes an orthotopic model of bladder cancer, in which MB49 murine bladder carcinoma cells are instilled into the bladder via catheterization. Successful tumor cell implantation in this model requires disruption of the protective glycosaminoglycan layer, which can be accomplished by physical or chemical means. In our protocol the bladder is treated with trypsin prior to cell instillation. Catheterization of the bladder can also be used to deliver therapeutics once the tumors are established. This protocol describes the delivery of an adenoviral construct that expresses a luciferase reporter gene. While our protocol has been optimized for short-term studies and focuses on gene delivery, the methodology of mouse bladder catheterization has broad applications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24326612      PMCID: PMC4011168          DOI: 10.3791/50181

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  29 in total

1.  Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder.

Authors:  R Daniel Bonfil; Daniela M Russo; M Mercedes Binda; François M Delgado; Marc Vincenti
Journal:  Urol Oncol       Date:  2002 Jul-Aug       Impact factor: 3.498

2.  Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).

Authors:  J H Günther; M Frambach; I Deinert; S Brandau; D Jocham; A Böhle
Journal:  J Urol       Date:  1999-05       Impact factor: 7.450

3.  Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo.

Authors:  A Böhle; A Jurczok; P Ardelt; T Wulf; A J Ulmer; D Jocham; S Brandau
Journal:  J Urol       Date:  2002-01       Impact factor: 7.450

4.  Optimizing syngeneic orthotopic murine bladder cancer (MB49).

Authors:  J H Günther; A Jurczok; T Wulf; S Brandau; I Deinert; D Jocham; A Böhle
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

5.  Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.

Authors:  Nathan A Bockholt; Matthew J Knudson; Jonathan R Henning; José L Maymí; Peter Weady; George J Smith; Michael D Eisenbraun; James D Fraser; Michael A O'Donnell; Yi Luo
Journal:  J Urol       Date:  2012-04-13       Impact factor: 7.450

6.  Retrovirus type C in the mouse bladder carcinoma cell line MBT-2.

Authors:  E C De Boer; J S Teppema; P A Steerenberg; W H De Jong
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

7.  Monitoring the response of orthotopic bladder tumors to granulocyte macrophage colony-stimulating factor therapy using the prostate-specific antigen gene as a reporter.

Authors:  Qinghui Wu; Kesavan Esuvaranathan; Ratha Mahendran
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

8.  Nonviral cytokine gene therapy on an orthotopic bladder cancer model.

Authors:  Qinghui Wu; Ratha Mahendran; Kesavan Esuvaranathan
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

9.  Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model.

Authors:  D Robert Siemens; Scott Crist; J Christopher Austin; James Tartaglia; Timothy L Ratliff
Journal:  J Urol       Date:  2003-09       Impact factor: 7.450

10.  Presence of heparin binding growth factor in mouse bladder tumors and urine from mice with bladder cancer.

Authors:  G W Chodak; Y Shing; M Borge; S M Judge; M Klagsbrun
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

View more
  7 in total

1.  Methods to assess anticancer immune responses in orthotopic bladder carcinomas.

Authors:  Randy F Sweis
Journal:  Methods Enzymol       Date:  2019-10-24       Impact factor: 1.600

2.  A Murine Orthotopic Bladder Tumor Model and Tumor Detection System.

Authors:  Sin Mun Tham; Kesavan Esuvaranathan; Ratha Mahendran
Journal:  J Vis Exp       Date:  2017-01-12       Impact factor: 1.355

3.  A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive Bladder Cancer.

Authors:  Vanessa Bellat; Adam O Michel; Charlene Thomas; Tracy Stokol; Benjamin B Choi; Benedict Law
Journal:  Cancer Res       Date:  2022-04-01       Impact factor: 12.701

4.  Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.

Authors:  Yunhua Liu; Hanchen Xu; Kevin Van der Jeught; Yujing Li; Sheng Liu; Lu Zhang; Yuanzhang Fang; Xinna Zhang; Milan Radovich; Bryan P Schneider; Xiaoming He; Cheng Huang; Chi Zhang; Jun Wan; Guang Ji; Xiongbin Lu
Journal:  J Clin Invest       Date:  2018-06-04       Impact factor: 14.808

5.  Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer.

Authors:  Helen Gosnell; Laura M Kasman; Thrimoorthy Potta; Lucas Vu; Elizabeth Garrett-Mayer; Kaushal Rege; Christina Voelkel-Johnson
Journal:  J Control Release       Date:  2013-12-24       Impact factor: 9.776

6.  In vivo biodistribution and toxicity of intravesical administration of quantum dots for optical molecular imaging of bladder cancer.

Authors:  Ying Pan; Timothy Chang; Gautier Marcq; Changhao Liu; Bernhard Kiss; Robert Rouse; Kathleen E Mach; Zhen Cheng; Joseph C Liao
Journal:  Sci Rep       Date:  2017-08-24       Impact factor: 4.379

7.  FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer.

Authors:  Yang Zhang; Fan Huo; Qiang Cao; Ru Jia; Qiju Huang; Zhu A Wang; Dan Theodorescu; Qiang Lv; Pengchao Li; Chao Yan
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.